Company
IQVIA is a healthcare data analytics company providing clinical research and real-world evidence services to pharmaceutical and life-sciences firms.
Hanmi Pharmaceutical's Eppe, Korea's first home-grown GLP-1 obesity drug, is approved and expected to launch at about half Wegovy's 200,000-won-plus price. Its trial weight loss trails both incumbents, so the launch price will set how much of a Mounjaro-dominated market it can reach.
Reality
Italy's privacy regulator fined IQVIA 7 million euros after finding coded records on about one million patients could be traced back to individuals. Teams that pool health records under one persistent patient key now have a regulator's written reasoning for why removing names fell short.
Reality
Hanmi Pharmaceutical's Eppe could launch in Korea before year-end at an estimated 150,000 won for four weeks, 45% below Mounjaro's cheapest listing. Lilly won about 85% of the market at a higher price than Wegovy, so Novo, which has cut once already, is the likelier incumbent to cut again.
Reality
The FDA is investigating whether GLP-1 drugs cause sudden vision loss, and the New Jersey filings number in the dozens. The market those drugs sell into is projected at $92 billion this year.
Reality
Six of the eight positions Harris Associates increased in Q2 2026 are banks, brokers, exchanges or payments processors. The other two are Salesforce and Sysco, and the trim list includes an insurer.
Reality
The Danish drugmaker will test Anthropic's science workbench on specific R&D workflows while an earlier company-wide OpenAI agreement keeps running alongside it. Bloomberg reported that financial terms were not disclosed.
Reality
Claude Science adds no new intelligence, only 60-plus database connectors and a reviewer agent. That was enough to move three research-tools vendors, and it reorders how you score AI suppliers.
Reality